BMX-001 is feasible during head and neck chemoradiotherapy, but radioprotection remains unproven
In 29 patients receiving BMX-001 with head and neck chemoradiotherapy, 41.4% developed grade 3 mucositis, without a randomized comparator.
In 29 patients receiving BMX-001 with head and neck chemoradiotherapy, 41.4% developed grade 3 mucositis, without a randomized comparator.
Grade ≥3 mucositis at week 6 occurred in 11.1% with benzydamine versus 70.6% with standard care.
Lithium mouthwash reduced severe oral mucositis from 52.1% to 34.2% in a randomized phase II head and neck radiotherapy trial.
Two blinded oncologists often assigned different peak toxicity grades, including grade 3 mucositis rates of 40.5% versus 17.6%.